The stock of Kadmon Holdings Inc (NYSE:KDMN) reached all time low today, Sep, 30 and still has $6.32 target or 13.00% below today’s $7.26 share price. This indicates more downside for the $314.89M company. This technical setup was reported by Barchart.com. If the $6.32 PT is reached, the company will be worth $40.94M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 69,559 shares traded hands or 1.85% up from the average. Kadmon Holdings Inc (NYSE:KDMN) has risen 6.00% since August 31, 2016 and is uptrending. It has underperformed by 4.42% the S&P500.
Kadmon Holdings Inc (NYSE:KDMN) Ratings Coverage
Out of 4 analysts covering Kadmon Holdings (NYSE:KDMN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Kadmon Holdings has been the topic of 4 analyst reports since August 22, 2016 according to StockzIntelligence Inc. The company was initiated on Monday, August 22 by JMP Securities. The stock has “Neutral” rating given by Citigroup on Monday, August 22. The rating was initiated by H.C. Wainwright on Monday, August 22 with “Buy”. Jefferies initiated the stock with “Buy” rating in Monday, August 22 report.
According to Zacks Investment Research, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York.”
More notable recent Kadmon Holdings Inc (NYSE:KDMN) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on July 26, 2016, also Businesswire.com with their article: “Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in …” published on September 21, 2016, Marketwatch.com published: “Sam Waksal’s Kadmon Holdings prices IPO” on July 26, 2016. More interesting news about Kadmon Holdings Inc (NYSE:KDMN) were released by: Businesswire.com and their article: “Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma” published on August 29, 2016 as well as Cnbc.com‘s news article titled: “Sam Waksal’s Kadmon Holdings shares open below offering price in debut” with publication date: July 27, 2016.
KDMN Company Profile
Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Firm is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company’s product candidates include KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It also offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.